Clinitech Laboratory board meetings: key actions in FY26

Clinitech Laboratory Limited, a Healthcare sector company in the Hospital and Healthcare Services industry, has reported a series of board meetings across FY2025-26 with specific corporate actions recorded for select dates. The latest disclosed board meeting was held on February 06, 2026, and the company also provided granular details for a meeting held on January 27, 2026. These updates matter because board decisions shape governance, compliance posture, and corporate structure, all of which investors track closely in newly listed and smaller healthcare names.

As of March 11, 2026, the share price of CTLLAB was reported at ₹40. The company is listed on BSE with scrip code 544220 and carries ISIN INE0QMR01015.

Company snapshot and listing identifiers

Clinitech Laboratory Limited is categorised under Healthcare, with industry classification listed as Hospital and Healthcare Services. On the market infrastructure side, the company’s equity is available on BSE under code 544220, and the ISIN disclosed is INE0QMR01015. The stock was referenced with the trading symbol CTLLAB, with a stated share price of ₹40 as on March 11, 2026.

The company’s public records also carry its registered office details in Navi Mumbai, Maharashtra, along with investor-facing contact coordinates such as email and website. These identifiers and contact points are typically referenced in exchange filings and board meeting intimations.

Registered office and registrar details

Clinitech Laboratory’s registered office address is AL-1/545, Sector 16, Airoli, Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, with the city listed as Thane, Maharashtra, PIN 400708. The telephone number provided is 022-45003240. The email listed for contact is info@clinitechlab.com, and the company website is http://www.ctllab.in.

For registrar and transfer agent services, the registrar address is listed as S6-2, 6th Floor, Pinnacle Business Park, Mumbai 400093, Maharashtra. The registrar telephone number is 022-62638200 and fax number is 022-62638261. The registrar email is investor@bigshareonline.com, and the website is http://www.bigshareonline.com.

February 06, 2026 board meeting: short, focused session

A board meeting was held on February 06, 2026. The disclosed meeting duration was 20 minutes, starting at 03:00 PM IST and ending at 03:20 PM IST. The text indicates that “decisions were made” during this focused session, but no specific agenda items or resolutions were detailed in the provided information.

While the absence of itemised outcomes limits analytical granularity, the precise time disclosure indicates a formally convened meeting with recorded proceedings. For investors, the key takeaway from this specific disclosure is timing and duration rather than the substance of decisions.

January 27, 2026 board meeting: subsidiary and POSH updates

Clinitech Laboratory’s board meeting held on January 27, 2026 included detailed timings and outcomes. The meeting started at 11:30 AM IST and ended at 12:00 PM IST, with a duration of 30 minutes. According to the disclosed outcome, the board approved the formation of a subsidiary company.

The same meeting also resulted in the reconstitution of the Internal Complaint Committee, along with a revised POSH policy. These actions are governance and compliance related and typically align with organisational readiness as operations scale or corporate structure evolves. The disclosure does not specify the name or jurisdiction of the proposed subsidiary, nor the content of the revised policy, so the only confirmed facts are the approval of subsidiary formation and the ICC reconstitution with a revised POSH policy.

FY2025-26 meeting trail: dates disclosed in filings

The available board meeting list for Clinitech Laboratory includes multiple dates and remark tags. The disclosed board meeting dates and remarks include: 25 Mar, 2025 (Others), 23 May, 2025 (Audited Results), 06 Jun, 2025 (Others), 19 Aug, 2025 (Others), 22 Nov, 2025 (board meeting intimation referenced), and earlier 13 Nov, 2024 (Half Yearly Results). Separately, meeting intimations also reference board meetings scheduled on March 25, 2025, May 23, 2025, and November 22, 2025.

This sequence reflects regular board cadence, with at least one meeting specifically tied to audited financial results for the year ended March 31, 2025.

What the company said for March to June 2025 agenda items

For the March 25, 2025 meeting, the intimation included consideration and approval of appointment of M/s. Kalpesh Khatri and Associates, Chartered Accountants as Internal Auditors of the company, and appointment of M/s. Deep Shukla and Associates as the Secretarial Auditors of the company. The intimation also included a standard “any other matter with the permission of the Chair” clause.

For the May 23, 2025 board meeting, the company stated the agenda included consideration and approval of the audited financial results of the company along with the auditor’s report for the half year and financial year ended March 31, 2025. The outcome note also referenced approval of financial results as on March 31, 2025.

For the June 06, 2025 meeting, the company disclosed that the board would take note of the resignation of Mr. Bharat Kumar Bohra from the post of Company Secretary and Compliance Officer, consider and approve appointment of a Company Secretary and Compliance Officer, and address other matters with the Chair’s permission.

Table: key factual identifiers and contact points

Table: board meetings and disclosed actions (selected)

Market context: why these items matter for shareholders

In smaller listed healthcare services companies, board decisions often provide some of the earliest signals of how governance and operating structure are being shaped. The January 27, 2026 approvals relate directly to corporate structure (subsidiary formation) and workplace compliance (POSH policy and Internal Complaint Committee). Even without further detail, these are formal governance actions and typically require board oversight.

Separately, the March to June 2025 disclosures highlight routine compliance and financial reporting cycles. The May 23, 2025 meeting being tagged to audited results for the year ended March 31, 2025 places it in the standard annual reporting calendar. Auditor appointments and changes in key compliance roles, such as Company Secretary and Compliance Officer, are also closely watched because they connect to ongoing exchange compliance and investor communication.

Conclusion: what to watch next in disclosures

The latest disclosed board meeting on February 06, 2026 was completed in 20 minutes, while the January 27, 2026 meeting recorded clear outcomes including approval of subsidiary formation and governance updates under POSH. The FY2025-26 board meeting trail also includes audited-results consideration for the year ended March 31, 2025 and governance-related agenda items such as auditor appointments and changes in compliance leadership.

Investors tracking Clinitech Laboratory may watch for follow-up filings that provide further detail on the February 06, 2026 decisions, and any subsequent disclosures on the proposed subsidiary and implementation of the revised POSH policy framework.